MyCural is a start-up life science company that specializes in developing new cancer therapies for patients with high-risk tumors. Founded by cancer researchers from Karolinska Institutet and Linköping University, our mission is to create a new cancer therapy by targeting the MYC oncoprotein, which is the main driver of more than 50% of all cancers. At MyCural Therapeutics, we focus on the development of potential candidate drugs that specifically target the MYC oncoprotein.

These small molecules were originally identified by cancer researchers at Karolinska Institutet and are now being developed by our dedicated team. Our vision is to provide patients with non-curable cancer an option for the future, offering a new therapy for those with aggressive, resistant, and metastasized high-risk tumors. With the expertise of our experienced team, including Dr.

Alina Castell, Prof. Lars-Gunnar Larsson, and Prof. Maria Sunnerhagen, we are committed to advancing cancer research and improving the lives of cancer patients.

For more information, please visit our website or contact us directly. Together, let's fight against cancer and make a difference in the lives of those affected